Investment trusts tap the profits in exotic and obscure global markets
Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money


Unicorn Mastertrust invests exclusively in investment trusts, aiming to deliver an attractive total return primarily in the form of capital growth. Trusts have a long and proud history dating back more than 150 years and have survived every conceivable geopolitical and economic disaster.
Donald Trump’s Liberation Day shenanigans will cause some headaches in the short term, but I am sure that investment companies will continue to serve investors well for decades to come. My confidence stems from a belief that an investment trust offers the best structure for successful investment in the long term. This is quite an assertion given that most fund assets around the world are in open-ended structures rather than closed-ended trusts.
The portfolio has a structural bias towards trusts that use their semi-permanent capital to invest in relatively illiquid assets on a global basis. Consequently, the fund has plenty of exposure to smaller companies (in the UK and overseas), listed private equity (LPE) trusts, and specialist trusts suitable only for a properly diversified portfolio.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Big potential in British small caps
The largest holding in the first category, the Aberforth Smaller Companies Trust (LSE: ASL), is not only the largest trust of its type but also the only one to have a value-investing approach. Applied consistently since launch in 1990, this investment style experienced a protracted period of underperformance in the low-interest rate period following the global financial crisis.
A further headwind for the portfolio, which comprises around 80 UK smaller companies, came with the Brexit vote, followed by an accelerating shift of capital towards the American growth story. The fundamental ratings of ASL’s investments became so cheap that corporate buyers were attracted to the market, leading to a surge in mergers and acquisitions, which looks set to endure.
The ICG Enterprise Trust (LSE: ICGT) is an LPE trust that invests in buyouts in North America and Europe. Typically, these investments in private companies would be expected to be realised or refinanced within a period of between five and seven years, but sales have been somewhat elusive over the last couple of years. Questions have therefore been raised about the validity of the valuations of LPE trusts, and Mr. Market has ruled on the issue by pushing discounts to net asset value (NAV) ever wider.
As a result, over the last five years, ICGT’s NAV has expanded at a compound annual growth rate (CAGR) of 13.8%, while the share price’s CAGR has been only 8.5%. The discount to NAV has reached a staggering 37%. Earlier this month, the managers announced the sale of around 5% of the portfolio at a level that provided strong validation of the NAV and released capital for new investments and share buybacks.
Go for gold
Gold is globally fungible and difficult to apply tariffs to. Its price can also be volatile, so my selection in the specialist trust category comes with a bumper wealth warning. Golden Prospect Precious Metals (LSE: GPM) invests in gold and precious metals companies.
The fund’s effective exposure to gold miners is 91%, with the balance in silver producers. If fears of tariff-driven stagflation and interest rates staying higher for longer prove right, and inflows continue into physical exchange-traded funds (ETFs), GPM could be one to watch.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Peter Walls is fund manager of the Unicorn Mastertrust Fund.
-
Could investing in sugar protect you during a downturn?
Sugar has some defensive qualities during economic downturns, but is now the right time to invest in sugar?
By Dan McEvoy
-
Trump’s tariffs: how should the UK respond?
Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism. So, what is Trump thinking?
By Stuart Watkins
-
Two top Asia-focused investment trusts
Pacific Assets and Scottish Oriental are both trusts that focus on high-quality companies controlled by trustworthy families or founders
By Max King
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine